Summary
Jazz Pharmaceuticals plc (Jazz) is a specialty biopharmaceutical company. It identifies, develops and commercializes novel therapeutic products with a focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for acute lymphoblastic leukemia; Prialt for severe chronic pain in patients who are intolerant or refractory to other treatments; FazaClo LD and FazaClo HD, orally disintegrating clozapine tablets indicated for treatment-resistant schizophrenia and Versacloz, for the treatment of schizophrenia. The company’s product pipeline includes new product candidates and line extensions for existing products and the generation of additional clinical data for existing products. The company’s product candidates include new lines of ErwinazeTM/Erwinase; Leukotac (inolimomab); and Asparec mPEG-r-crisantaspase). The company sells its products through a network of local distributors and wholesalers in more than 80 countries. It has operations in the US, Bermuda and France. Jazz is headquartered Dublin, Ireland.
Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2010 to YTD 2016 11
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
EUSA Pharma Acquires Rights to Arcoral Tab from Arcoral Pharma 15
Essex Bidco Acquires Assets from Jazz Pharma 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 19
Venture Financing 20
EUSA Pharma Raises Funds in Venture Financing 20
Partnerships 21
Canbridge Life Sciences Enters into Co-Marketing Agreement with Eusa Pharma for Caphosol 21
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 22
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 23
Superna Life Sciences Enters into Distribution Agreement with EUSA Pharma 24
Merger 25
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 25
Licensing Agreements 27
EUSA Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib 27
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 29
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 30
Gentium Enters Into Licensing Agreement With Medison Pharma For Defibrotide 32
Jazz Pharma Enters Into Sub-Licensing Agreement With Anchen 33
EUSA Pharma Enters Into Licensing Agreement With Ohara Pharma 34
Gentium Enters Into Licensing Agreement With Sigma-Tau Pharma 35
Equity Offering 37
Jazz Pharma Terminates Private Placement Of Common Stock For US$75 Million 37
Jazz Pharma Completes Public Offering Of US$58.45 Million 39
Debt Offering 41
Jazz Pharma Prices Private Placement of Senior Notes Due 2021 for USD500 Million 41
Asset Transactions 42
Aytu BioScience Acquires ProstaScint from Jazz Pharma 42
Essex Bidco Acquires Assets from Jazz Pharma 43
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 44
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 45
Acquisition 47
AstraZeneca May Acquire Ariad Pharma 47
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 49
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 51
Jazz Pharmaceuticals Plc - Key Competitors 54
Key Employees 55
Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
List of Tables
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2010 to YTD 2016 9
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2010 to YTD 2016 11
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
EUSA Pharma Acquires Rights to Arcoral Tab from Arcoral Pharma 15
Essex Bidco Acquires Assets from Jazz Pharma 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 19
EUSA Pharma Raises Funds in Venture Financing 20
Canbridge Life Sciences Enters into Co-Marketing Agreement with Eusa Pharma for Caphosol 21
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 22
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 23
Superna Life Sciences Enters into Distribution Agreement with EUSA Pharma 24
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 25
EUSA Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib 27
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 29
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 30
Gentium Enters Into Licensing Agreement With Medison Pharma For Defibrotide 32
Jazz Pharma Enters Into Sub-Licensing Agreement With Anchen 33
EUSA Pharma Enters Into Licensing Agreement With Ohara Pharma 34
Gentium Enters Into Licensing Agreement With Sigma-Tau Pharma 35
Jazz Pharma Terminates Private Placement Of Common Stock For US$75 Million 37
Jazz Pharma Completes Public Offering Of US$58.45 Million 39
Jazz Pharma Prices Private Placement of Senior Notes Due 2021 for USD500 Million 41
Aytu BioScience Acquires ProstaScint from Jazz Pharma 42
Essex Bidco Acquires Assets from Jazz Pharma 43
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 44
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 45
AstraZeneca May Acquire Ariad Pharma 47
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 49
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 51
Jazz Pharmaceuticals Plc, Key Competitors 54
Jazz Pharmaceuticals Plc, Key Employees 55
Jazz Pharmaceuticals Plc, Other Locations 56
Jazz Pharmaceuticals Plc, Subsidiaries 56
List of Figures
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2010 to YTD 2016 11
